Abstract
Colonization of the gastrointestinal tract with multidrug-resistant (MDR) bacteria is a consequence of gut dysbiosis. We describe the successful utilization of fecal microbiota transplantation to inhibit Klebsiella pneumoniae MBL(+) and Escherichia coli ESBL(+) gut colonization in the immunocompromised host as a novel tool in the battle against MDR microorganisms. ClinicalTrials.gov identifier NCT02461199.
Keywords:
Antibiotic-resistant bacteria; Fecal microbiota transplantation; Gut colonization.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use*
-
Antineoplastic Agents / adverse effects
-
Drug Resistance, Bacterial
-
Drug Resistance, Multiple
-
Dysbiosis / therapy
-
Escherichia coli
-
Fecal Microbiota Transplantation / methods*
-
Female
-
Humans
-
Immunocompromised Host*
-
Intestinal Mucosa / microbiology*
-
Klebsiella pneumoniae
-
Male
-
Microbiota
-
Middle Aged
-
Multiple Myeloma / complications
-
Multiple Myeloma / drug therapy
-
Phenotype
-
Young Adult
Substances
-
Anti-Bacterial Agents
-
Antineoplastic Agents
Associated data
-
ClinicalTrials.gov/NCT02461199